As on Wednesday, Akero Therapeutics Inc (NASDAQ: AKRO) got off with the flyer as it spiked 0.96% to $20.08, before settling in for the price of $19.89 at the close. Taking a more long-term approach, AKRO posted a 52-week range of $11.25-$58.38.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 0.00%. Meanwhile, its Annual Earning per share during the time was 1.03%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -33.21%. This publicly-traded company’s shares outstanding now amounts to $69.15 million, simultaneously with a float of $57.79 million. The organization now has a market capitalization sitting at $1.39 billion. At the time of writing, stock’s 50-day Moving Average stood at $24.49, while the 200-day Moving Average is $28.44.
Akero Therapeutics Inc (AKRO) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Akero Therapeutics Inc’s current insider ownership accounts for 16.42%, in contrast to 82.69% institutional ownership. According to the most recent insider trade that took place on Apr 01 ’24, this organization’s Chief Operating Officer sold 5,000 shares at the rate of 24.38, making the entire transaction reach 121,913 in total value, affecting insider ownership by 263,306. Preceding that transaction, on Mar 13 ’24, Company’s President and CEO sold 1,969 for 28.33, making the whole transaction’s value amount to 55,782. This particular insider is now the holder of 589,447 in total.
Akero Therapeutics Inc (AKRO) Earnings and Revenue Records
If we go through the results of last quarter, which was made public on 12/31/2023, the company posted -0.55 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.67) by 0.12. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.97 per share during the current fiscal year.
Akero Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -33.21% and is forecasted to reach -4.32 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -14.60% through the next 5 years, which can be compared against the 1.03% growth it accomplished over the previous five years trading on the market.
Akero Therapeutics Inc (NASDAQ: AKRO) Trading Performance Indicators
Let’s observe the current performance indicators for Akero Therapeutics Inc (AKRO). It’s Quick Ratio in the last reported quarter now stands at 29.27. The Stock has managed to achieve an average true range (ATR) of 1.22.
In the same vein, AKRO’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.85, a figure that is expected to reach -0.90 in the next quarter, and analysts are predicting that it will be -4.32 at the market close of one year from today.
Technical Analysis of Akero Therapeutics Inc (AKRO)
Through scrutinizing the latest numbers posted by the [Akero Therapeutics Inc, AKRO], it can be observed that its last 5-days Average volume of 0.77 million was lower the volume of 1.22 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 47.86% While, its Average True Range was 1.09.
Raw Stochastic average of Akero Therapeutics Inc (AKRO) in the period of the previous 100 days is set at 21.96%, which indicates a major fall in contrast to 44.76% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 44.66% that was lower than 66.04% volatility it exhibited in the past 100-days period.
